Corrections of non-material nature to the previously communicated Year-end Report for Vigmed Holding AB, January 1 – December 31 2013
ET | Source:Vigmed Holding AB
Vigmed Holding AB published its Year-end Report on February 26; unfortunately,
the company has retrospectively discovered some non-material errors in the
published version why a revised communiqué is published now.
In the press release submitted February 26 it was stated that the operating
result of the Group for the fourth quarter was MSEK -.5 MSEK and for the full
year MSEK -21.8. The correct operating result for the fourth quarter was MSEK
-5.5 and for the full year MSEK -22.2, which is consistent with the submitted
Year-end Report attached to the press release.
Further, the comparative figures for 2012 in the Group Income Statement were not
entirely accurate, in the table and the text references. The errors in the
figures for 2012 numbers arose as a consequence of an error in a report in the
financial system that has now been corrected.
Vigmed attaches an accurate report, and regrets any inconvenience caused.
The Board of Directors of Vigmed Holding AB
For further information, please see Vigmeds Year-end Report
For further information contact:
Chairman of the board, Lennart Holm, 46 70-630 8562 or
CEO, Finn Ketler, 46 42 600 5311
Vigmed is a Swedish medical technology company whose mission is to eliminate
needlestick injuries by offering the market unique needle-protected products.
Vigmed is headquartered in Helsingborg, Sweden, and has approximately 15
employees. Vigmed’s share is traded on NASDAQ OMX First North in Stockholm
(ticker VIG) and has approximately 5 400 shareholders. Remium Nordic AB is the
Company’s Certified Advisor.
Additional information such as company description, a video presentation and
risk factors can be found on Vigmed’s website:
GlobeNewswire, a Nasdaq company, is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.
2321 Rosecrans Avenue.
El Segundo, CA 90245 Phone: (800) 307-6627 Fax: (800) 307-3567
25 Basinghall Street,
London EC2V 5HA
UK Phone: +1 866-465-8454